Deliberation, Unjust Exclusion, and the Rhetorical Turn

Theories of deliberative democracy have faced the charge of leading to the unjust exclusion of voices from public deliberation. The recent rhetorical turn in deliberative theory aims to respond to this charge. I distinguish between two variants of this response: the supplementing approach and the systemic approach. On the supplementing approach, rhetorical modes of political speech may legitimately supplement the deliberative process, for the sake of those excluded from the latter. On the systemic approach, rhetorical modes of political speech are legitimate within public deliberation, just so long as they result in net benefits to the deliberative system. I argue that neither of these two approaches adequately meets the unjust exclusion charge. Whereas the supplementing approach does not go far enough to incorporate rhetorical speech into public deliberation, the systemic approach goes too far by legitimizing forms of rhetoric that risk only exacerbating the problem of unjust exclusion. More constructively, I draw on Aristotle’s conception of rhetoric, as an art (technē) that is a counterpart to dialectic, to argue for a constitutive approach to rhetoric. I show how this approach provides a more expansive notion of deliberation that remains normatively orientated

United States Bureau of Mines Bulletin 8190

Report issued by the Bureau of Mines over tests conducted on underground mine slimes from a collection sump. Testing methods and results are discussed. This report includes tables, illustrations, and photographs

Limited field tests in electrokinetic densification of mill tailings /

Bibliography: p. 44.Mode of access: Internet

Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination

PURPOSE: The coronavirus disease 2019 (COVID-19) pandemic has led to the approval of novel vaccines with different mechanisms of action. Until now, more than 4.7 billion persons have been vaccinated around the world, and adverse effects not observed in pre-authorization trials are being reported at low frequency. METHODS: We report a case of severe hemophagocytic lymphohistiocytosis (HLH) after SARS-CoV-2 immunization and performed a literature search for all reported cases of COVID-19 vaccine-associated HLH. RESULTS: A 24-year-old female developed HLH after immunization with the mRNA COVID-19 vaccine Comirnaty. Diagnosis was made according to HLH-2004 criteria; the HScore was 259 (> 99% HLH probability) with maximum ferritin of 138.244 µg/L. The patient was initially treated with intravenous immunoglobulins (IVIGs) and dexamethasone without response. The addition of the human interleukin 1 receptor antagonist Anakinra resulted in full recovery within 6 weeks after vaccination. A literature search revealed 15 additional cases of HLH after SARS-CoV-2 vaccination, the majority after immunization with Comirnaty (n = 7) or the viral vector vaccine Vaxzevria (n = 6). Treatment modalities included corticosteroids (n = 13), Anakinra (n = 5), IVIGs (n = 5), and etoposide (n = 2). Eight patients underwent combination treatment. Three of 16 patients died. CONCLUSION: COVID-19 vaccines may occasionally trigger HLH, and Anakinra may be an efficacious treatment option for this condition

Fission coincident particle emission from 64^{64}Ni + 165^{165}Ho at 12.2 Mev/U

this article presents a survey about differents approaches of information in the organizations. Management and sociology are useful but leave information activity aside. A better understanding may help to study the evolution of information management

Laboratory experiments in electrokinetic densification of mill tailings (in two parts).

Includes bibliographical references (p. 64-65).Part 1 - Development of equipment and procedures -- Part 2 - Application to various types and classifications of tailings.Mode of access: Internet

Sichtverbesserungssysteme

Die Verkehrsunfälle bei Nacht haben schwere volkswirtschaftliche Folgen. Nach K. Rumar [1] betrugen die abgeschätzten Kosten der Straßenverkehrsunfälle im Jahr 1999 mehr als 160 Milliarden Euro, etwa doppelt soviel wie der Etat der EU-Länder in dem betrachteten Zeitraum. Für die Analyse in diesem Kapitel können für eine aussagekräftige Unfallforschung die Daten des Instituts für Fahrzeugsicherheit in München hinzugezogen werden [2]. Demnach zeigen Unfälle mit Fußgängerbeteiligung je nach Ortslage unterschiedliche Schwerpunkte. Ein Drittel der 43789 Unfälle mit verletzten Fußgängern im Jahr 1995 fand in der Dunkelheit und Dämmerung statt. Etwa 60 % aller 1336 Unfälle mit getöteten Fußgängern im Jahr 1995 ereigneten sich in der Dunkelheit. Für Innerortsunfälle waren 84 % der beteiligten Fußgänger zum Zeitpunkt des Unfalls dunkel gekleidet. Nach [2] war bei 70 % der untersuchten Unfälle die Straßenbeleuchtung in Betrieb und wurde subjektiv als gut beurteilt. Die hier ausgeführten Auswertungen der nächtlichen Verkehrsunfälle basieren auf den Daten der Bundesanstalt für Straßenwesen im Jahr 2005 [3], die die Einzeldaten der amtlichen Straßenverkehrsunfallstatistik der Jahre 1991 bis 2002 bewertete. Diese Daten gelten sinngemäß für die heutigen Verkehrssituationen. Dabei gibt es viele Aspekte, mit denen die Ursache für Verkehrsunfälle untersucht und charakterisiert werden kann. Einige davon sind: ..

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and constraints in administration routes. Despite the need for more antifungal drug options, no new classes of antifungal drugs have become available over the last 2 decades, and only one single new agent from a known antifungal class has been approved in the last decade. Nevertheless, there is hope on the horizon, with a number of new antifungal classes in late-stage clinical development. In this review, we describe the mechanisms of drug resistance employed by fungi and extensively discuss the most promising drugs in development, including fosmanogepix (a novel Gwt1 enzyme inhibitor), ibrexafungerp (a first-in-class triterpenoid), olorofim (a novel dihyroorotate dehydrogenase enzyme inhibitor), opelconazole (a novel triazole optimized for inhalation), and rezafungin (an echinocandin designed to be dosed once weekly). We focus on the mechanism of action and pharmacokinetics, as well as the spectrum of activity and stages of clinical development. We also highlight the potential future role of these drugs and unmet needs